ICON Public (NASDAQ:ICLR) Reaches New 1-Year Low – What’s Next?

ICON Public Limited (NASDAQ:ICLR) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $179.50 and last traded at $184.41, with a volume of 158879 shares changing hands. The stock had previously closed at $190.02.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $263.00 price target on shares of ICON Public in a research report on Wednesday, January 15th. Robert W. Baird reduced their price target on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating for the company in a research report on Tuesday. Barclays dropped their price objective on ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a report on Friday, February 21st. William Blair reissued an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. Finally, Truist Financial cut their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $279.17.

ICON Public Stock Up 1.6 %

The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The firm’s 50-day moving average price is $200.78 and its 200 day moving average price is $238.28. The firm has a market capitalization of $15.06 billion, a price-to-earnings ratio of 19.57, a price-to-earnings-growth ratio of 1.86 and a beta of 1.19.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The firm had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. Sell-side analysts expect that ICON Public Limited will post 13.38 EPS for the current year.

Institutional Trading of ICON Public

Large investors have recently bought and sold shares of the company. Sierra Ocean LLC acquired a new stake in shares of ICON Public during the fourth quarter worth $29,000. Park Place Capital Corp raised its holdings in ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after purchasing an additional 166 shares in the last quarter. Private Trust Co. NA boosted its stake in ICON Public by 48.8% during the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after buying an additional 82 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares in the last quarter. Finally, Horizon Investments LLC lifted its position in shares of ICON Public by 534.0% during the 4th quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after acquiring an additional 550 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.